Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.08 Million EUR | -60.59% |
| 2022 | 33.21 Million EUR | -3.68% |
| 2021 | 34.47 Million EUR | 22.29% |
| 2020 | 28.19 Million EUR | 33.28% |
| 2019 | 21.15 Million EUR | 197.25% |
| 2018 | 7.11 Million EUR | -6.0% |
| 2017 | 7.57 Million EUR | 7.06% |
| 2016 | 7.07 Million EUR | 794.06% |
| 2015 | 791 Thousand EUR | -65.62% |
| 2014 | 2.3 Million EUR | 3.0% |
| 2013 | 2.23 Million EUR | -8.52% |
| 2012 | 2.44 Million EUR | -0.41% |
| 2011 | 2.45 Million EUR | 17.88% |
| 2010 | 2.08 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 6.38 Million EUR | 0.0% |
| 2023 Q3 | 13.08 Million EUR | -54.22% |
| 2023 Q4 | 13.08 Million EUR | 0.0% |
| 2023 Q1 | 28.59 Million EUR | -13.91% |
| 2023 FY | 13.08 Million EUR | -60.59% |
| 2023 Q2 | 28.59 Million EUR | 0.0% |
| 2022 FY | 33.21 Million EUR | -3.68% |
| 2022 Q3 | 33.21 Million EUR | 5.25% |
| 2022 Q4 | 33.21 Million EUR | 0.0% |
| 2022 Q2 | 31.55 Million EUR | 0.0% |
| 2022 Q1 | 31.55 Million EUR | -8.49% |
| 2021 Q3 | 34.47 Million EUR | 22.64% |
| 2021 Q4 | 34.47 Million EUR | 0.0% |
| 2021 Q1 | 28.11 Million EUR | -0.29% |
| 2021 FY | 34.47 Million EUR | 22.29% |
| 2021 Q2 | 28.11 Million EUR | 0.0% |
| 2020 Q2 | 20.95 Million EUR | -0.0% |
| 2020 Q1 | 20.95 Million EUR | -0.96% |
| 2020 Q3 | 28.19 Million EUR | 34.57% |
| 2020 Q4 | 28.19 Million EUR | 0.0% |
| 2020 FY | 28.19 Million EUR | 33.28% |
| 2019 Q2 | 8.08 Million EUR | 0.0% |
| 2019 Q4 | 21.15 Million EUR | 0.0% |
| 2019 FY | 21.15 Million EUR | 197.25% |
| 2019 Q1 | 8.08 Million EUR | 13.66% |
| 2019 Q3 | 21.15 Million EUR | 161.53% |
| 2018 Q3 | 7.11 Million EUR | -9.65% |
| 2018 FY | 7.11 Million EUR | -6.0% |
| 2018 Q4 | 7.11 Million EUR | 0.01% |
| 2018 Q2 | 7.87 Million EUR | -2.05% |
| 2018 Q1 | 8.04 Million EUR | 6.21% |
| 2017 Q1 | 7 Million EUR | -0.95% |
| 2017 Q2 | 7 Million EUR | 0.0% |
| 2017 Q3 | 7.57 Million EUR | 8.09% |
| 2017 Q4 | 7.57 Million EUR | -0.01% |
| 2017 FY | 7.57 Million EUR | 7.06% |
| 2016 Q2 | 6.18 Million EUR | -1.18% |
| 2016 FY | 7.07 Million EUR | 794.06% |
| 2016 Q1 | 6.26 Million EUR | 691.4% |
| 2016 Q3 | 7.07 Million EUR | 14.32% |
| 2016 Q4 | 7.07 Million EUR | 0.0% |
| 2015 Q3 | 837 Thousand EUR | -34.3% |
| 2015 Q2 | 1.27 Million EUR | -6.53% |
| 2015 FY | 791 Thousand EUR | -65.62% |
| 2015 Q1 | 1.36 Million EUR | -40.76% |
| 2015 Q4 | 791 Thousand EUR | -5.5% |
| 2014 Q2 | 2.25 Million EUR | -5.56% |
| 2014 Q3 | 2.3 Million EUR | 1.9% |
| 2014 Q4 | 2.3 Million EUR | 0.0% |
| 2014 Q1 | 2.39 Million EUR | 7.03% |
| 2014 FY | 2.3 Million EUR | 3.0% |
| 2013 Q1 | 2.08 Million EUR | -14.58% |
| 2013 Q4 | 2.23 Million EUR | 0.0% |
| 2013 Q2 | 2.08 Million EUR | 0.0% |
| 2013 Q3 | 2.23 Million EUR | 7.09% |
| 2013 FY | 2.23 Million EUR | -8.52% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 Q4 | 2.44 Million EUR | 0.0% |
| 2012 FY | 2.44 Million EUR | -0.41% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 FY | 2.45 Million EUR | 17.88% |
| 2011 Q4 | 2.45 Million EUR | 0.0% |
| 2010 FY | 2.08 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -286.077% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 76.403% |
| Aelis Farma SA | 4.03 Million EUR | -224.121% |
| Biophytis S.A. | 8.27 Million EUR | -58.259% |
| Advicenne S.A. | 17.42 Million EUR | 24.89% |
| genOway Société anonyme | 7.23 Million EUR | -80.938% |
| IntegraGen SA | 1.12 Million EUR | -1063.652% |
| Medesis Pharma S.A. | 1.2 Million EUR | -990.667% |
| Neovacs S.A. | 650 Thousand EUR | -1913.538% |
| NFL Biosciences SA | 62.17 Thousand EUR | -20950.6% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -200.424% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -381.736% |
| Sensorion SA | 2.86 Million EUR | -356.221% |
| Theranexus Société Anonyme | 3.64 Million EUR | -259.262% |
| TME Pharma N.V. | 1.16 Million EUR | -1022.47% |
| Valbiotis SA | 6.87 Million EUR | -90.288% |
| TheraVet SA | 1.15 Million EUR | -1028.405% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -45.455% |
| argenx SE | 18.1 Million EUR | 27.712% |
| BioSenic S.A. | 28.16 Million EUR | 53.524% |
| Celyad Oncology SA | 902 Thousand EUR | -1350.998% |
| DBV Technologies S.A. | 13.01 Million USD | -0.533% |
| Galapagos NV | 9.59 Million EUR | -36.39% |
| Genfit S.A. | 70.17 Million EUR | 81.35% |
| GeNeuro SA | 7.73 Million EUR | -69.144% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -147.223% |
| Innate Pharma S.A. | 39.89 Million EUR | 67.192% |
| Inventiva S.A. | 37.4 Million EUR | 65.012% |
| MaaT Pharma SA | 14.07 Million EUR | 7.012% |
| MedinCell S.A. | 58.96 Million EUR | 77.802% |
| Nanobiotix S.A. | 50.56 Million EUR | 74.116% |
| Onward Medical N.V. | 16.87 Million EUR | 22.437% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 4.378% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 71.424% |
| Oxurion NV | 12.33 Million EUR | -6.113% |
| Pharming Group N.V. | 155.29 Million EUR | 91.572% |
| Poxel S.A. | 46.9 Million EUR | 72.094% |
| GenSight Biologics S.A. | 18.42 Million EUR | 28.978% |
| Transgene SA | 1.25 Million EUR | -941.209% |
| Financière de Tubize SA | 79.2 Million EUR | 83.475% |
| UCB SA | 3.03 Billion EUR | 99.569% |
| Valneva SE | 208.81 Million EUR | 93.732% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -34342.105% |